Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers

• Published in: Biochemical pharmacology 2022-04, Vol.198, p.114963-114963, Article 114963
• Main Authors: Scotton, Ellen, Antqueviezc, Bárbara, Vasconcelos, Mailton França de, Dalpiaz, Giovana, Paul Géa, Luiza, Ferraz Goularte, Jéferson, Colombo, Rafael, Ribeiro Rosa, Adriane
• Format: Article
• Language: English
• Subjects: (R)-ketamine; (S)-ketamine; Antidepressive Agents - adverse effects; Depression - metabolism; Depressive Disorder, Major - drug therapy; Humans; Ketamine - adverse effects; Ketamine enantiomers; Neuroplasticity; Racemic ketamine; Receptors, N-Methyl-D-Aspartate - metabolism; Treatment resistant depression
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2022.114963

[Display omitted] Approximately one-third of individuals with major depressive disorder are resistant to conventional antidepressants (i.e., monoamine-based therapies), and, even among respondents, a proper therapeutic effect may require weeks of treatment. Ketamine, a racemic mixture of the two enantiomers, (R)-ketamine and (S)-ketamine, is an N-methyl-d-aspartate receptor (NMDAR) antagonist and has been shown to have rapid-acting antidepressant properties in patients with treatment-resistant depression (TRD). Although (R)-ketamine has a lower affinity for NMDAR, it presents greater potency and longer-lasting antidepressant properties, with no major side effects, than racemic ketamine or (S)-ketamine in preclinical findings. Thereby, ketamine and its enantiomers have not only an antagonistic effect on NMDAR but also a strong synaptogenic-modulatory effect, which is impaired in TRD pathophysiology. In this review, we summarize the current evidence regarding the modulation of neurotransmission, neuroplasticity, and neural network activity as putative mechanisms of these rapid-acting antidepressants, highlighting differences on intracellular signaling pathways of synaptic proteins such as mammalian target of rapamycin (mTOR), extracellular signal-regulated kinase (ERK) and brain-derived neurotrophic factor (BDNF). In addition, we discuss probable mechanisms involved in the side effects of ketamine and its enantiomers.